Articles

RSS

Click Here To Download:
•Article: Delivery Technology Reenergizes DNA Drug Development

By Drew Hannaman, Robert Bernard, and May de las Alas

In vivo delivery of DNA-based biopharmaceutical agents encoding proteins of interest ("DNA drugs") offers a means for the production of protein by target regions of tissue in a subject. This product class derives activity from an ability to induce sustained endogenous protein expression from recipients' own cells. These unique characteristics are favorable for multiple applications, several of which are now in clinical testing.

Reprinted with permission from BioProcess International

Click Here To Download:
•Article: Delivery Technology Reenergizes DNA Drug Development